Detection of prostate cancer biomarkers via a SERS-based aptasensor.
Biosens Bioelectron
; 216: 114660, 2022 Nov 15.
Article
em En
| MEDLINE
| ID: mdl-36099835
ABSTRACT
The overexpression of specific biomarkers in serum is closely related to diseases, and accurate and sensitive detection of them is beneficial for the early diagnosis and treatment of cancer. In this study, we developed a novel surface-enhanced Raman spectroscopy (SERS)-based aptasensor to detect the prostate-specific antigen biomarkers, consisting of total prostate-specific antigen (PSA) and free prostate-specific antigen (f-PSA). A composite structure containing arrays of polystyrene colloidal sphere @Ag shell (PS@Ag) was fabricated as a SERS-active chip. A complementary DNA probe (SH-DNA) and PSA aptamer (Apt) were immobilised stepwise on the chip, followed by the binding of a Raman reporter methylene blue (MB) to the guanine base of the aptamer. PSA-Apt recognition causes the release of MB-Apt and a decrease in the SERS intensity of MB on the chip, which correlates with the PSA concentration. The proposed biosensor has high spectral reproducibility, selectivity, and sensitivity and successfully determines the PSA levels in serum samples collected from prostate cancer patients, demonstrating great potential for clinical diagnosis.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Técnicas Biossensoriais
/
Aptâmeros de Nucleotídeos
/
Nanopartículas Metálicas
Tipo de estudo:
Diagnostic_studies
/
Screening_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
Biosens Bioelectron
Ano de publicação:
2022
Tipo de documento:
Article